US equities |
NVDA $236.58 ▲+1.12% SPCX $164.89 ▲+3.73% MU $1,065.01 ▼-0.92% TSLA $379.07 ▲+2.29% MSFT $525.76 ▲+1.59% INTC $116.85 ▼-2.08% SNDK $1,721.50 ▲+0.09% AMD $628.96 ▼-0.78%
FinancialContent

Articles published by AgomAb Therapeutics NV

News headline image
Agomab Reports Positive Topline Data from STENOVA Open-Label Extension Study of Ontunisertib in Fibrostenosing Crohn's Disease
From AgomAb Therapeutics NV
Via GlobeNewswire
Tickers AGMB
News headline image
Agomab Announces Positive Phase 1 Results for AGMB-447 in Patients with Idiopathic Pulmonary Fibrosis and Design of Phase 2 INSPIRIA Study
From AgomAb Therapeutics NV
Via GlobeNewswire
Tickers AGMB
News headline image
Agomab Announces Appointments of Marino Garcia and Dr. Naimish Patel to Board of Directors
From AgomAb Therapeutics NV
Via GlobeNewswire
Tickers AGMB
News headline image
Agomab to Participate in Upcoming Investor Conferences
From AgomAb Therapeutics NV
Via GlobeNewswire
Tickers AGMB
News headline image
Agomab Announces Proposed Appointments of Marino Garcia and Dr. Naimish Patel to Board of Directors
From AgomAb Therapeutics NV
Via GlobeNewswire
Tickers AGMB
News headline image
Agomab Reports Half Year 2026 Financial Results and Confirms 2026 Outlook
From AgomAb Therapeutics NV
Via GlobeNewswire
Tickers AGMB
News headline image
Agomab Announces Design of NOV-ERA Phase 2b Study with Ontunisertib in Fibrostenosing Crohn’s Disease
From AgomAb Therapeutics NV
Via GlobeNewswire
Tickers AGMB
News headline image
Agomab Announces Results of Annual General Meeting
From AgomAb Therapeutics NV
Via GlobeNewswire
Tickers AGMB
News headline image
Agomab to Participate in Upcoming Conferences
From AgomAb Therapeutics NV
Via GlobeNewswire
Tickers AGMB
News headline image
Agomab Reports Full Year 2025 Financial Results and Confirms 2026 Outlook
From AgomAb Therapeutics NV
Via GlobeNewswire
Tickers AGMB
News headline image
Late-Breaking Interim STENOVA Data for AGMB-129 in Fibrostenosing Crohn’s to be Presented at Digestive Disease Week® 2025
From Agomab Therapeutics NV
Via Business Wire
News headline image
Agomab Announces Positive Topline Phase 2a Interim Results for AGMB-129 in Fibrostenosing Crohn’s Disease
From Agomab Therapeutics NV
Via Business Wire
News headline image
Agomab Announces $89 Million Series D Financing to Support Broad Fibrosis-Focused Pipeline
From Agomab Therapeutics NV
Via Business Wire
News headline image
Agomab Bolsters Executive Team with Appointment of Pierre Kemula as Chief Financial Officer
From Agomab Therapeutics NV
Via Business Wire
News headline image
Agomab Appoints Industry Veteran David Epstein as Chairman of its Board of Directors
From Agomab Therapeutics NV
Via Business Wire
News headline image
Agomab Receives FDA Orphan Drug Designation for AGMB-447 in Idiopathic Pulmonary Fibrosis
From Agomab Therapeutics NV
Via Business Wire
News headline image
Agomab Starts Phase 1 Clinical Study for AGMB-447 in Healthy Subjects and Patients with Idiopathic Pulmonary Fibrosis
From Agomab Therapeutics NV
Via Business Wire
News headline image
Agomab Raises $100 Million Series C to Advance Fibrosis-focused Pipeline
From Agomab Therapeutics NV
Via Business Wire
News headline image
Agomab Reports Positive Phase 1 Results with AGMB-129, a GI-restricted ALK5 Inhibitor for Fibrostenosing Crohn’s Disease
From Agomab Therapeutics NV
Via Business Wire
News headline image
Agomab Raises Additional $40.5 Million Through Series B Extension Bringing Total Amount to $114 Million
From Agomab Therapeutics NV
Via Business Wire
News headline image
Agomab to Present at 40th Annual J.P. Morgan Healthcare Conference and Announces Additional Upcoming Conference Participations in Q1
From Agomab Therapeutics NV
Via Business Wire
News headline image
Agomab Expands Team with Reginald Brys as Head of Research and Maria Nichol as Head of IP
From Agomab Therapeutics NV
Via Business Wire
News headline image
Agomab Therapeutics Completes Acquisition of Origo Biopharma
From Agomab Therapeutics NV
Via Business Wire